Sage Journals: Discover world-class research

Abstract

Background

The impact of methylene blue (MB) on critical patient outcomes, including overall mortality, hemodynamic stability, and organ function has been inconsistently described across studies. This study aims to evaluate the efficacy of MB therapy in adult patients with septic shock in the intensive care unit (ICU).

Methods

The systematic search of PubMed/MEDLINE, EMBASE and Cochrane Library databases up to February 2024 included randomized controlled trials and prospective observational studies involving adult septic shock patients who received intravenous MB therapy. The primary outcome was all-cause mortality, with secondary outcomes on hemodynamics and ICU length of stay.

Results

Fifteen studies (5 randomized, 10 non-randomized) involving a total of 441 patients, met the inclusion criteria. The meta-analysis showed statistically significant reduction in mortality rates among septic shock patients treated with MB (mortality rate 0.52; 95% CI 0.38 to 0.66; P < .001). In a sub-analysis of only randomized trials, the results remained statistically significant (risk ratio 0.66; 95% CI 0.47 to 0.94; P = .023). A significant increase in mean arterial pressure post-infusion was observed in three studies. Two studies showed no substantial difference in heart rate and two studies showed no difference in cardiac index following MB administration. Only one study showed a reduction in the length of ICU stay with MB use, while another observed a decrease in overall hospital length of stay.

Conclusions

The review and meta-analysis suggest that MB may be associated with a significant reduction in mortality in septic shock patients though findings are limited by sample size and heterogeneity. Further robust studies are needed to validate these results.

Keywords

septic shock methylene blue mortality intensive care

Get full access to this article

View all access options for this article.

References

Zhao

Zhai

Huo

Zhu

. Efficacy and safety of methylene blue in patients with vasodilatory shock: A systematic review and meta-analysis. Front Med (Lausanne). 2022;9(1):950596. doi:10.3389/fmed.2022.950596.

Evans

Rhodes

Alhazzani

, et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181‐1247. doi:10.1007/s00134-021-06506-y.

Fleischmann

Scherag

Adhikari

NKJ

, et al. Assessment of global incidence and mortality of hospital-treated sepsis current estimates and limitations. Am J Respir Crit Care Med. 2016;193(3):259‐272. doi:10.1164/rccm.201504-0781OC.

Lamontagne

Richards-Belle

Thomas

, et al. Effect of reduced exposure to vasopressors on 90-day mortality in older critically ill patients with vasodilatory hypotension: A randomized clinical trial. JAMA – J Am Med Assoc. 2020;323(10):938‐949. doi:10.1001/jama.2020.0930.

Jentzer

Vallabhajosyula

Khanna

Chawla

Busse

Kashani

. Management of refractory vasodilatory shock. Chest. 2018;154(2):416‐426. doi:10.1016/j.chest.2017.12.021.

Puntillo

Giglio

Pasqualucci

Brienza

Paladini

Varrassi

. Vasopressor-Sparing action of methylene blue in severe sepsis and shock: A narrative review. Adv Ther. 2020;37(9):3692‐3706. doi:10.1007/s12325-020-01422-x.

Leone

Einav

Antonucci

, et al. Multimodal strategy to counteract vasodilation in septic shock. Anaesth Crit Care Pain Med. 2023;42(3). doi:10.1016/j.accpm.2023.101193.

Cauwels

. Nitric oxide in shock. Kidney Int. 2007;72(5):557‐565. doi:10.1038/sj.ki.5002340.

Evora

PRB

Viaro

. The guanylyl cyclase inhibition by MB as vasoplegic circulatory shock therapeutical target. Curr Drug Targets. 2006;7(9):1195‐1204. doi:10.2174/138945006778226679.

10.

Tchen

Sullivan

. Clinical utility of midodrine and methylene blue as catecholamine-sparing agents in intensive care unit patients with shock. J Crit Care. 2020;57:148‐156. doi:10.1016/j.jcrc.2020.02.011.

11.

Methylene Blue | C16H18ClN3S | CID 6099 – PubChem. Accessed April 30, 2024. https://pubchem.ncbi.nlm.nih.gov/compound/Methylene-Blue

12.

Albertson

Chenoweth

Lewis

Pugashetti

Sandrock

Morrissey

. The pharmacotherapeutic options in patients with catecholamine-resistant vasodilatory shock. Expert Rev Clin Pharmacol. 2022;15(8):959‐976. doi:10.1080/17512433.2022.2110067.

13.

Huang

Yan

Chen

Qian

. Effect of methylene blue on outcomes in patients with distributive shock: A meta-analysis of randomised controlled trials. BMJ Open. 2024;14(1). doi:10.1136/bmjopen-2023-080065.

14.

Pruna

Bonaccorso

Belletti

, et al. Methylene blue reduces mortality in critically ill and perioperative patients: A meta-analysis of randomized trials. J Cardiothorac Vasc Anesth. 2024;38(1):268‐274. doi:10.1053/j.jvca.2023.09.037.

15.

Ballarin

Lazzarin

Zornoff

, et al. Methylene blue in sepsis and septic shock: a systematic review and meta-analysis. Front Med (Lausanne). 2024;11. doi:10.3389/fmed.2024.1366062.

16.

Fernando

Tran

Soliman

, et al. Methylene blue in septic shock: A systematic review and meta-analysis. Crit Care Explor. 2024;6(7):e1110. doi:10.1097/CCE.0000000000001110.

17.

Huang

Yan

Chen

Qian

. Effect of methylene blue on outcomes in patients with distributive shock: A meta-analysis of randomised controlled trials. BMJ Open. 2024;14(1):e080065. doi:10.1136/bmjopen-2023-080065.

18.

Higgins

Thomas

Chandler

, et al., eds. Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (Updated August 2023). Cochrane; 2023.

19.

Page

McKenzie

Bossuyt

, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Br Med J. Published online March 29, 2021:n71. doi:10.1136/bmj.n71

20.

Stroup

Berlin

Morton

. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA. 2000;283(15):2008. doi:10.1001/jama.283.15.2008.

21.

Sterne

JAC

Savović

Page

, et al. Rob 2: A revised tool for assessing risk of bias in randomised trials. Br Med J. 2019;366:l4898. doi:10.1136/bmj.l4898.

22.

Stang

. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603‐605. doi:10.1007/s10654-010-9491-z.

23.

Andresen

Dougnac

Díaz

, et al. Use of methylene blue in patients with refractory septic shock: Impact on hemodynamics and gas exchange. J Crit Care. 1998;13(4):164‐168. doi:10.1016/s0883-9441(98)90001-6.

24.

Daemen-Gubbels

Groeneveld

van Kamp

Bronsveld

Thijs

. Methylene blue increases myocardial function in septic shock. Crit Care Med. 1995;23(8):1363‐1370. doi:10.1097/00003246-199508000-00009.

25.

Donati

Conti

Loggi

, et al. Does methylene blue administration to septic shock patients affect vascular permeability and blood volume? Published online 2002. doi:10.1097/01.CCM.0000029185.70149.5F

26.

Gachot

Bedos

Veber

Wolff

Regnier

Short-Term Effects of Methylene Blue on Hemodynamics and Gas Exchange in Humans with Septic Shock, Vol. 21. Springer-Verlag; 1995.

27.

van Haren

FMP

Pickkers

Foudraine

Heemskerk

Sleigh

van der Hoeven

. The effects of methylene blue infusion on gastric tonometry and intestinal fatty acid binding protein levels in septic shock patients. J Crit Care. 2010;25(2):358.e1‐358.e7. doi:10.1016/j.jcrc.2010.02.008.

28.

Heemskerk

Van Haren

FMP

Foudraine

, et al. Short-term beneficial effects of methylene blue on kidney damage in septic shock patients. Intensive Care Med. 2008;34(2):350‐354. doi:10.1007/s00134-007-0867-9.

29.

Ibarra-Estrada

Kattan

Aguilera-González

, et al. Early adjunctive methylene blue in patients with septic shock: a randomized controlled trial. Crit Care. 2023;27(1). doi:10.1186/s13054-023-04397-7.

30.

Juffermans

Vervloet

Daemen-Gubbels

CRG

Binnekade

Jong

Groeneveld

ABJ

. A dose-finding study of methylene blue to inhibit nitric oxide actions in the hemodynamics of human septic shock. Nitric Oxide. 2010;22(4):275‐280. doi:10.1016/j.niox.2010.01.006.

31.

Kirov

Evgenov

, et al. Infusion of methylene blue in human septic shock: A pilot, randomized, controlled study. Crit Care Med. 2001;29(10):1860‐1867. doi:10.1097/00003246-200110000-00002.

32.

Memis

Karamanlioglu

Yuksel

Gemlik

Pamukcu

. The influence of methylene blue infusion on cytokine levels during severe sepsis. Anaesth Intensive Care. 2002;30(6):755‐762. doi:10.1177/0310057X0203000606.

33.

Rajbanshi

Bajracharya

Arjyal

Devkota

. Can use of intravenous methylene blue improve the hemodynamics and outcome of the patients with refractory septic shock? An observational study. Indian J Crit Care Med. 2023;27(9):669‐674. doi:10.5005/jp-journals-10071-24535.

34.

Weingartner

Oliveira

, et al. Blockade of the action of nitric oxide in human septic shock increases systemic vascular resistance and has detrimental effects on pulmonary function after a short infusion of methylene blue. Braz J Med Biol Res. 1999;32(12):1505‐1513. doi:10.1590/S0100-879X1999001200009.

35.

Park

Shim

Lim

, et al. The effects of methylene blue on hemodynamic parameters and cytokine levels in refractory septic shock. Korean J Intern Med. 2005;20(2):123. doi:10.3904/kjim.2005.20.2.123.

36.

Liu

Yao

Zhu

. Efficacy of continuous intravenous infusion of methylene blue in patients with septic shock. National Med J China. 2019;99:4.

37.

. Application of methylene blue in septic shock. Diet Health. 2021;9:79.

38.

Fleischmann-Struzek

Mellhammar

Rose

, et al. Incidence and mortality of hospital- and ICU-treated sepsis: Results from an updated and expanded systematic review and meta-analysis. Intensive Care Med. 2020;46(8):1552‐1562. doi:10.1007/s00134-020-06151-x.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.02 MB

0.05 MB

0.04 MB